2型糖尿病患者胰岛素治疗结构化管理模式研究:一项开放、多中心、前瞻性RCT研究

2012-11-21 北京大学第一医院 郭晓蕙 等 中国医学论坛报

  近年来,糖尿病患者教育在糖尿病防治中的作用日益受到重视,人们逐渐认识到糖尿病教育是糖尿病整体医疗护理中的重要组成部分。胰岛素结构化管理项目是基于糖尿病教育的重要内容,通过逐次随访,将各个模块的内容教育给患者,以促进糖尿病药物治疗效果。本研究观察和评估了在药物治疗效果不佳的2型糖尿病患者中进行结构化管理(OPENING干预)后,精蛋白重组人胰岛素注射液对患者临床疗效的影响。研究结果显示,对于口服

  近年来,糖尿病患者教育在糖尿病防治中的作用日益受到重视,人们逐渐认识到糖尿病教育是糖尿病整体医疗护理中的重要组成部分。胰岛素结构化管理项目是基于糖尿病教育的重要内容,通过逐次随访,将各个模块的内容教育给患者,以促进糖尿病药物治疗效果。本研究观察和评估了在药物治疗效果不佳的2型糖尿病患者中进行结构化管理(OPENING干预)后,精蛋白重组人胰岛素注射液对患者临床疗效的影响。研究结果显示,对于口服降糖药治疗持续3个月以上血糖控制不佳的2型糖尿病患者,经结构化管理后使用精蛋白重组人胰岛素注射液治疗,可使患者血糖得到有效控制,主要的疗效指标均明显改善,而且安全性及耐受性良好。整个治疗过程中患者对结构化管理具有良好的满意度。表明通过结构化管理可进一步增强患者的胰岛素联合用药疗效。

 

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1749384, encodeId=2f321e4938400, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 21:47:00 CST 2013, time=2013-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006354, encodeId=3706200635408, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat May 25 17:47:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903890, encodeId=c34f1903890d7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Sep 22 02:47:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383125, encodeId=201c1383125fd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473673, encodeId=c94414e36735f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514602, encodeId=e05b151460297, content=<a href='/topic/show?id=c8d68389847' target=_blank style='color:#2F92EE;'>#胰岛素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83898, encryptionId=c8d68389847, topicName=胰岛素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e51610667367, createdName=zjshifan_98647309, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625305, encodeId=46bd162530589, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
    2013-05-06 baoya
  2. [GetPortalCommentsPageByObjectIdResponse(id=1749384, encodeId=2f321e4938400, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 21:47:00 CST 2013, time=2013-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006354, encodeId=3706200635408, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat May 25 17:47:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903890, encodeId=c34f1903890d7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Sep 22 02:47:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383125, encodeId=201c1383125fd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473673, encodeId=c94414e36735f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514602, encodeId=e05b151460297, content=<a href='/topic/show?id=c8d68389847' target=_blank style='color:#2F92EE;'>#胰岛素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83898, encryptionId=c8d68389847, topicName=胰岛素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e51610667367, createdName=zjshifan_98647309, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625305, encodeId=46bd162530589, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1749384, encodeId=2f321e4938400, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 21:47:00 CST 2013, time=2013-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006354, encodeId=3706200635408, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat May 25 17:47:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903890, encodeId=c34f1903890d7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Sep 22 02:47:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383125, encodeId=201c1383125fd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473673, encodeId=c94414e36735f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514602, encodeId=e05b151460297, content=<a href='/topic/show?id=c8d68389847' target=_blank style='color:#2F92EE;'>#胰岛素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83898, encryptionId=c8d68389847, topicName=胰岛素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e51610667367, createdName=zjshifan_98647309, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625305, encodeId=46bd162530589, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1749384, encodeId=2f321e4938400, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 21:47:00 CST 2013, time=2013-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006354, encodeId=3706200635408, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat May 25 17:47:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903890, encodeId=c34f1903890d7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Sep 22 02:47:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383125, encodeId=201c1383125fd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473673, encodeId=c94414e36735f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514602, encodeId=e05b151460297, content=<a href='/topic/show?id=c8d68389847' target=_blank style='color:#2F92EE;'>#胰岛素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83898, encryptionId=c8d68389847, topicName=胰岛素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e51610667367, createdName=zjshifan_98647309, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625305, encodeId=46bd162530589, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1749384, encodeId=2f321e4938400, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 21:47:00 CST 2013, time=2013-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006354, encodeId=3706200635408, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat May 25 17:47:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903890, encodeId=c34f1903890d7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Sep 22 02:47:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383125, encodeId=201c1383125fd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473673, encodeId=c94414e36735f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514602, encodeId=e05b151460297, content=<a href='/topic/show?id=c8d68389847' target=_blank style='color:#2F92EE;'>#胰岛素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83898, encryptionId=c8d68389847, topicName=胰岛素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e51610667367, createdName=zjshifan_98647309, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625305, encodeId=46bd162530589, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1749384, encodeId=2f321e4938400, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 21:47:00 CST 2013, time=2013-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006354, encodeId=3706200635408, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat May 25 17:47:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903890, encodeId=c34f1903890d7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Sep 22 02:47:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383125, encodeId=201c1383125fd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473673, encodeId=c94414e36735f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514602, encodeId=e05b151460297, content=<a href='/topic/show?id=c8d68389847' target=_blank style='color:#2F92EE;'>#胰岛素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83898, encryptionId=c8d68389847, topicName=胰岛素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e51610667367, createdName=zjshifan_98647309, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625305, encodeId=46bd162530589, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1749384, encodeId=2f321e4938400, content=<a href='/topic/show?id=be7c8385345' target=_blank style='color:#2F92EE;'>#胰岛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83853, encryptionId=be7c8385345, topicName=胰岛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a7a536274692, createdName=baoya, createdTime=Mon May 06 21:47:00 CST 2013, time=2013-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2006354, encodeId=3706200635408, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sat May 25 17:47:00 CST 2013, time=2013-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903890, encodeId=c34f1903890d7, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Sun Sep 22 02:47:00 CST 2013, time=2013-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1383125, encodeId=201c1383125fd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473673, encodeId=c94414e36735f, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514602, encodeId=e05b151460297, content=<a href='/topic/show?id=c8d68389847' target=_blank style='color:#2F92EE;'>#胰岛素治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83898, encryptionId=c8d68389847, topicName=胰岛素治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e51610667367, createdName=zjshifan_98647309, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625305, encodeId=46bd162530589, content=<a href='/topic/show?id=604fe6046b2' target=_blank style='color:#2F92EE;'>#管理模式#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76046, encryptionId=604fe6046b2, topicName=管理模式)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8adf20737369, createdName=zhangj7115, createdTime=Fri Nov 23 01:47:00 CST 2012, time=2012-11-23, status=1, ipAttribution=)]

相关威廉亚洲官网

Diabetes Care:2型糖尿病遗传易感性与心血管并发症相关

  来自美国马萨诸塞州研究者的一项前瞻性研究表明,2型糖尿病的遗传易感性与2型糖尿病患者心血管并发症的风险增加呈正相关。研究在2012年10月15日在线发表于《糖尿病护理》(Diabetes Care)杂志。   该研究旨在探讨2型糖尿病(T2DM)遗传易感性与2型糖尿病患者心血管疾病(CVD)风险的相关性。研究共纳入健康专业人员随访研究和护士健康研究的1012例男性和1310例女性T

Lancet:利拉鲁肽每和艾塞那肽均可改善2型糖尿病患者血糖控制

  现已证实,胰高糖素样肽(GLP)-1激动剂艾塞那肽和利拉鲁肽可改善2型糖尿病患者血糖控制并减轻体重。DURATION-6(比较艾塞那肽每周1次与利拉鲁肽每日1次治疗2型糖尿病)最新结果表明,利拉鲁肽每日一次和艾塞那肽每周一次均可改善血糖控制,利拉鲁肽组血糖降低更多。结合此结果和药物的注射频率和耐受性,可有助于2型糖尿病患者的治疗决策。该研究11月7日在线发表于《柳叶刀》(Lancet)杂志。

Diabetes Care:PWV或可评估2型糖尿病脑血管病危险

  丹麦研究者研究发现,控制良好的2型糖尿病患者的颈-股脉搏波速度(PWV)较对照组更高,并与大脑白质损伤(WML)独立相关。PWV或可作为2型糖尿病脑血管疾病危险评估的临床相关参数。该研究2012年11月5日在线发表于《糖尿病护理》(Diabetes Care)杂志。   2型糖尿病患者包括卒中在内的心脑血管事件发生率很高。在普通人群中,动脉僵硬度的增高可预测心血管事件,WML与卒中

BJC:2型糖尿病女性患乳腺癌风险增加

  糖尿病本身虽不致命,但与多种严重疾病密切相关。关于糖尿病与癌症之间关系的研究很多,《英国癌症杂志》近日刊登的法国里昂国际预防研究所的一项研究发现,患有2型糖尿病的绝经后女性患乳腺癌的风险明显增加,同为风险因素的还有超重与肥胖。   首席研究员彼得·博伊尔教授表示,2型糖尿病患者罹患乳腺癌的风险增加27%,但这仅限于绝经后的女性。患有2型糖尿病的绝经前女性或患有1型糖尿病的女性罹患乳腺癌的风险

AIM:含豆类的低血糖指数饮食降低心血管危险

  加拿大学者进行的研究表明, 2型糖尿病患者将豆类作为低血糖指数(GI)饮食,既能改善血糖控制,也能降低心血管危险。文章发表于10月22日出版的《内科学文献》(Arch Intern Med)杂志。   研究者将121例2型糖尿病患者随机分为2组,一组给予低GI豆类饮食(鼓励患者增加豆类摄入每天至少1杯),另一组给予全麦纤维饮食,共3个月。   结果显示,低GI

NIH:减重不能降低2型糖尿病心血管风险

  美国国立卫生研究院(National Institutes of Health,NIH)资助的一项研究显示,2型糖尿病患者通过强化饮食和运动减肥,并不能降低心脏病、中风等心血管疾病的发生率。   这项糖尿病患者健康行动研究(Action for Health in Diabetes, AHEAD)共调查了美国16个研究中心的5145名超重及肥胖者的2型糖尿病患者,并将他们随机分成两组,一组接